(Q38068141)

28 August 2017

1 reference

title

Role of C5b-9 complement complex and response gene to complement-32 (RGC-32) in cancer (English)

1 reference

28 August 2017

Sonia I Vlaicu

1

1 reference

28 August 2017

Cosmin A Tegla

2

1 reference

28 August 2017

Cornelia D Cudrici

3

1 reference

28 August 2017

Jacob Danoff

4

1 reference

28 August 2017

Hassan Madani

5

1 reference

28 August 2017

Adam Sugarman

6

1 reference

28 August 2017

Florin Niculescu

7

1 reference

28 August 2017

Petru A Mircea

8

1 reference

28 August 2017

Violeta Rus

9

1 reference

28 August 2017

Horea Rus

10

1 reference

28 August 2017

1 May 2013

1 reference

28 August 2017

1 reference

28 August 2017

56

1 reference

28 August 2017

1

1 reference

28 August 2017

109-121

1 reference

https://scigraph.springernature.com/pub.10.1007/s12026-012-8381-8

28 August 2017

0 references

cites work

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12026-012-8381-8

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-012-8381-8

Inflammation and cancer: back to Virchow?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-012-8381-8

21 January 2018

Inflammation and cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12026-012-8381-8

Cancer-related inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-012-8381-8

Is complement good or bad for cancer patients? A new perspective on an old dilemma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-012-8381-8

Tumor immunoediting and immunosculpting pathways to cancer progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-012-8381-8

Cancer and the complement cascade

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-012-8381-8

Dual roles of immune cells and their factors in cancer development and progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-012-8381-8

Interactions between lymphocytes and myeloid cells regulate pro- versus anti-tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-012-8381-8

Paradoxical roles of the immune system during cancer development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-012-8381-8

Ascitic complement system in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-012-8381-8

Dual role of complement in tumour growth and metastasis (Review).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-012-8381-8

Activation of complement system in adult T-cell leukemia (ATL) occurs mainly through lectin pathway: a serum proteomic approach using mass spectrometry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-012-8381-8

Beyond lysis: how complement influences cell fate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-012-8381-8

Protection of thyroid cancer cells by complement-regulatory factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-012-8381-8

Immunoglobulin G expression and its colocalization with complement proteins in papillary thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-012-8381-8

Plasma proteomic analysis of patients with squamous cell carcinoma of the uterine cervix

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-012-8381-8

Cytolysis of nucleated cells by complement: cell death displays multi-hit characteristics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-012-8381-8

Membrane attack by complement: the assembly and biology of terminal complement complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-012-8381-8

Cancer resistance to complement-dependent cytotoxicity (CDC): Problem-oriented research and development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-012-8381-8

Programmed necrotic cell death induced by complement involves a Bid-dependent pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-012-8381-8

Cell signals transduced by complement

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-012-8381-8

Complement resistance of human carcinoma cells depends on membrane regulatory proteins, protein kinases and sialic acid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-012-8381-8

Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-012-8381-8

Complement membrane attack complexes induce in human leukemic cells rapid expression of large proteins (L-CIP).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-012-8381-8

On the brotherhood of the mitochondrial chaperones mortalin and heat shock protein 60.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-012-8381-8

Emission of membrane vesicles: roles in complement resistance, immunity and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-012-8381-8

Role of the C5b-9 complement complex in cell cycle and apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-012-8381-8

Mechanisms of signal transduction activated by sublytic assembly of terminal complement complexes on nucleated cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-012-8381-8

The role of c5b-9 terminal complement complex in activation of the cell cycle and transcription

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-012-8381-8

The Fos family of transcription factors and their role in tumourigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-012-8381-8

C5b-9-induced endothelial cell proliferation and migration are dependent on Akt inactivation of forkhead transcription factor FOXO1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-012-8381-8

The proliferating role of insulin and insulin-like growth factors in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-012-8381-8

C5b-9 terminal complement complex protects oligodendrocytes from death by regulating Bad through phosphatidylinositol 3-kinase/Akt pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-012-8381-8

Sublytic complement protects prostate cancer cells from tumour necrosis factor-α-induced cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-012-8381-8

C5b-9 terminal complex protects oligodendrocytes from apoptotic cell death by inhibiting caspase-8 processing and up-regulating FLIP

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-012-8381-8

Tumor metastasis: molecular insights and evolving paradigms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-012-8381-8

Metastasis: new perspectives on an old problem

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-012-8381-8

Cellular membrane type-1 matrix metalloproteinase (MT1-MMP) cleaves C3b, an essential component of the complement system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-012-8381-8

Interference with the complement system by tumor cell membrane type-1 matrix metalloproteinase plays a significant role in promoting metastasis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-012-8381-8

Cell-surface receptor for complement component C1q (gC1qR) is a key regulator for lamellipodia formation and cancer metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-012-8381-8

Complement C1q activates tumor suppressor WWOX to induce apoptosis in prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-012-8381-8

Complement-dependent control of teratoma formation by embryonic stem cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-012-8381-8

Fifth complement cascade protein (C5) cleavage fragments disrupt the SDF-1/CXCR4 axis: further evidence that innate immunity orchestrates the mobilization of hematopoietic stem/progenitor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-012-8381-8

Defective engraftment of C3aR-/- hematopoietic stem progenitor cells shows a novel role of the C3a-C3aR axis in bone marrow homing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-012-8381-8

Novel insight into stem cell mobilization-plasma sphingosine-1-phosphate is a major chemoattractant that directs the egress of hematopoietic stem progenitor cells from the bone marrow and its level in peripheral blood increases during mobilization d

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-012-8381-8

Modulation of the antitumor immune response by complement

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-012-8381-8

The complement system: history, pathways, cascade and inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-012-8381-8

Human lung cancer cell lines express cell membrane complement inhibitory proteins and are extremely resistant to complement-mediated lysis; a comparison with normal human respiratory epithelium in vitro, and an insight into mechanism(s) of resistanc

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-012-8381-8

Exceptional resistance of human H2 glioblastoma cells to complement-mediated killing by expression and utilization of factor H and factor H-like protein 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-012-8381-8

Upregulated expression of complement inhibitory proteins on bladder cancer cells and anti-MUC1 antibody immune selection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-012-8381-8

Immune evasion of tumor cells using membrane-bound complement regulatory proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-012-8381-8

Molecular cloning and characterization of RGC-32, a novel gene induced by complement activation in oligodendrocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-012-8381-8

Intracellular signal transduction pathway proteins as targets for cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-012-8381-8

RGC-32 increases p34CDC2 kinase activity and entry of aortic smooth muscle cells into S-phase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-012-8381-8

RGC32, a novel p53-inducible gene, is located on centrosomes during mitosis and results in G2/M arrest

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-012-8381-8

Overexpression of RGC-32 in colon cancer and other tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-012-8381-8

Role of response gene to complement 32 in diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-012-8381-8

Epigenetic modifications induced by RGC-32 in colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-012-8381-8

Upregulation of the cell-cycle regulator RGC-32 in Epstein-Barr virus-immortalized cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-012-8381-8

Discovery of epigenetically masked tumor suppressor genes in endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-012-8381-8

Response gene to complement 32, a novel hypoxia-regulated angiogenic inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-012-8381-8

Response gene to complement 32 is required for C5b-9 induced cell cycle activation in endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-012-8381-8

Response gene to complement 32 promotes vascular lesion formation through stimulation of smooth muscle cell proliferation and migration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-012-8381-8

Response gene to complement 32 interacts with Smad3 to promote epithelial-mesenchymal transition of human renal tubular cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-012-8381-8

Response gene to complement-32 enhances metastatic phenotype by mediating transforming growth factor beta-induced epithelial-mesenchymal transition in human pancreatic cancer cell line BxPC-3

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-012-8381-8

The Runx genes: lineage-specific oncogenes and tumor suppressors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-012-8381-8

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-012-8381-8

Response gene to complement 32 expression is induced by the luteinizing hormone (LH) surge and regulated by LH-induced mediators in the rodent ovary

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-012-8381-8

Response gene to complement 32, a novel regulator for transforming growth factor-beta-induced smooth muscle differentiation of neural crest cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-012-8381-8

Deposits of terminal complement complex (TCC) in muscularis mucosae and submucosal vessels in ulcerative colitis and Crohn's disease of the colon

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-012-8381-8

Expression of complement regulating factors in gastric cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-012-8381-8

Consequences of cell membrane attack by complement: release of arachidonate and formation of inflammatory derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-012-8381-8

Sublytic complement attack protects tumor cells from lytic doses of antibody and complement

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-012-8381-8

Live cell imaging of outward and inward vesiculation induced by the complement c5b-9 complex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-012-8381-8

Response of SCC-12F, a human squamous cell carcinoma cell line, to complement attack

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-012-8381-8

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-012-8381-8

Elimination of terminal complement complexes in the plasma membrane of nucleated cells: influence of extracellular Ca2+ and association with cellular Ca2+

21 January 2018

1 reference

12 December 2020

Ultrastructural studies of complement mediated cell death: a biological reaction model to plasma membrane injury

1 reference

12 December 2020

Inhibition of oligodendrocyte apoptosis by sublytic C5b-9 is associated with enhanced synthesis of bcl-2 and mediated by inhibition of caspase-3 activation

1 reference

12 December 2020

Generation of diacylglycerol and ceramide during homologous complement activation.

1 reference

12 December 2020

Arachidonic acid mobilization and phosphoinositide turnover by the terminal complement complex, C5b-9, in rat oligodendrocyte x C6 glioma cell hybrids.

1 reference

12 December 2020

The terminal complement complex inhibits apoptosis in vascular smooth muscle cells by activating an autocrine IGF-1 loop

1 reference

12 December 2020

Elimination of terminal complement intermediates from the plasma membrane of nucleated cells: the rate of disappearance differs for cells carrying C5b-7 or C5b-8 or a mixture of C5b-8 with a limited number of C5b-9

1 reference

12 December 2020

Sublytic complement attack induces cell cycle in oligodendrocytes.

1 reference

12 December 2020

Mortalin inhibitors sensitize K562 leukemia cells to complement-dependent cytotoxicity

1 reference

12 December 2020

High Expression of Complement Component 5 (C5) at Tumor Site Associates with Superior Survival in Ewing's Sarcoma Family of Tumour Patients

1 reference

12 December 2020

Persistent complement activation on tumor cells in breast cancer

1 reference

12 December 2020

Terminal complement complexes induce cell cycle entry in oligodendrocytes through mitogen activated protein kinase pathway

1 reference

12 December 2020

Cell desensitization by sublytic C5b-9 complexes and calcium ionophores depends on activation of protein kinase C.

1 reference

12 December 2020

Receptor-independent activation of guanine nucleotide-binding regulatory proteins by terminal complement complexes.

1 reference

12 December 2020

Activation of Ras and mitogen-activated protein kinase pathway by terminal complement complexes is G protein dependent

1 reference

12 December 2020

Multiple signal messengers generated by terminal complement complexes and their role in terminal complement complex elimination

1 reference

12 December 2020

Human carcinomas variably express the complement inhibitory proteins CD46 (membrane cofactor protein), CD55 (decay-accelerating factor), and CD59 (protectin).

1 reference

12 December 2020

Detection of complement C3 and factor B gene expression in normal colorectal mucosa, adenomas and carcinomas

1 reference

12 December 2020

Sublytic C5b-9 induces proliferation of human aortic smooth muscle cells: role of mitogen activated protein kinase and phosphatidylinositol 3-kinase

1 reference

12 December 2020

Tyrosine phosphorylation and activation of Janus kinase 1 and STAT3 by sublytic C5b-9 complement complex in aortic endothelial cells

1 reference

12 December 2020

Quantitative analysis of adenine nucleotides during the prelytic phase of cell death mediated by C5b-9.

1 reference

12 December 2020

Frequent expression of complement resistance factors CD46, CD55, and CD59 on gastrointestinal cancer cells limits the therapeutic potential of monoclonal antibody 17-1A

1 reference

12 December 2020

Promoter methylation of the RGC32 gene in nonsmall cell lung cancer

1 reference

12 December 2020

The inhibitory effect of CD46, CD55, and CD59 on complement activation after immunotherapeutic treatment of cervical carcinoma cells with monoclonal antibodies or bispecific monoclonal antibodies

1 reference

12 December 2020

Nucleated cell killing by complement: effects of C5b-9 channel size and extracellular Ca2+ on the lytic process.

1 reference

12 December 2020

Immunohistochemical expression and prognostic value of CD97 and its ligand CD55 in primary gallbladder carcinoma

1 reference

12 December 2020

10.1007/S12026-012-8381-8

Identifiers

DOI

1 reference

Dimensions Publication ID

28 August 2017

0 references

1 reference